Search - tctmd.com

Displaying 1 - 20 of 98

Sort: Relevancy | Date

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

L.A. McKeown

September 05, 2025

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

L.A. McKeown

April 24, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Daily News

Philips Recalls Tack Endovascular Systems and Stops Distribution

L.A. McKeown

March 03, 2025

News Daily News

FDA Issues Early Alert About Risks of Peripheral Atherectomy Device

L.A. McKeown

February 07, 2025

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

L.A. McKeown

November 06, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Daily News

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

L.A. McKeown

September 12, 2023

News Daily News

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

L.A. McKeown

July 11, 2023

News Daily News

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

L.A. McKeown

March 29, 2023

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

Advertisement

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

Philips Recalls Tack Endovascular Systems and Stops Distribution

FDA Issues Early Alert About Risks of Peripheral Atherectomy Device

Top Endovascular News of 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

FDA Approves Bioresorbable Scaffold for BTK Lesions

Top Endovascular News of 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content